Niva Bupa Health

Why is Niva Bupa Health Insurance Company Ltd falling/rising?

As of 07-Aug, Niva Bupa Health Insurance Company's stock price is declining, currently at 86.06, reflecting a 1.3% decrease. Despite strong long-term fundamentals, short-term market sentiment has led to a significant drop in investor participation and negative performance trends.

As of 07-Aug, Niva Bupa Health Insurance Company Ltd's stock price is falling, currently at 86.06, which reflects a decrease of 1.13 or 1.3%. The stock has been on a downward trend, having lost 1.79% over the last two days and opened today with a loss of 2.2%. Additionally, it touched an intraday low of Rs 85.27. <BR><BR>The stock's performance over the past week and month has also been negative, with declines of 1.03% and 0.53%, respectively, while the benchmark Sensex has shown positive returns during these periods. Furthermore, there has been a significant drop in investor participation, with delivery volume falling by 72.5% compared to the 5-day average, indicating reduced trading interest. <BR><BR>Despite these short-term challenges, the company has strong long-term fundamentals, including a 137.70% CAGR growth in operating profits and a healthy annual growth rate of 43.20% in net sales. However, the current market sentiment appears to be affecting the stock negatively in the short term.

Which are the latest news on Niva Bupa Health?

Are Niva Bupa Health Insurance Company Ltd latest results good or bad?

Niva Bupa Health Insurance Company's Q1 FY27 results are generally positive, with a 92.93% year-on-year net profit increase to ₹137.80 crores and a 28.56% revenue growth. However, a 13.54% sequential profit decline and a below-average return on equity indicate areas for improvement.

Niva Bupa Health Insurance Company Ltd's latest results for Q1 FY27 can be considered good overall, despite some mixed signals. The company reported a net profit of ₹137.80 crores, which is a remarkable increase of 92.93% year-on-year. Additionally, revenue grew by 28.56% to ₹2,273.72 crores, indicating strong top-line momentum.<BR><BR>The operating margin improved to 8.10%, up from 5.55% in the same quarter last year, reflecting better operational efficiency and cost management. However, it's worth noting that the net profit decreased by 13.54% compared to the previous quarter, which raises some concerns about sequential performance.<BR><BR>While the company has demonstrated significant revenue growth and improved profitability metrics, its return on equity (ROE) of 4.56% remains below industry averages, indicating challenges in capital efficiency. This aspect could be a concern for investors looking for strong returns on their investments.<BR><BR>In summary, while Niva Bupa's quarterly results show strong growth and operational improvements, the decline in sequential profit and lower ROE suggest that there are still areas for the company to address. Overall, the results reflect a positive trajectory, but caution is warranted regarding sustainability and capital efficiency moving forward.

Should I buy, sell or hold Niva Bupa Health Insurance Company Ltd?

When is the next results date for Niva Bupa Health Insurance Company Ltd?

The next results date for Niva Bupa Health Insurance Company Ltd is July 30, 2026.

The next results date for Niva Bupa Health Insurance Company Ltd is scheduled for July 30, 2026.

What does Niva Bupa Health do?

Niva Bupa Health Insurance Company Ltd, originally Max Bupa, operates in the insurance sector and reported net sales of ₹1,972 Cr and a net profit of ₹345 Cr for Q1 2026, with a market cap of ₹15,497 Cr. Key metrics include a P/E ratio of 118.00 and a debt-equity ratio of 0.07.

Overview:<BR>Niva Bupa Health Insurance Company Ltd operates in the insurance industry and is categorized as a small-cap company.<BR><BR>History:<BR>Niva Bupa Health Insurance Company Limited was originally incorporated as Max Bupa Health Insurance Limited in 2008. The company was granted its Certificate for Commencement of Business on December 23, 2008. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,972 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 345 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 15,497 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 118.00 <BR>Industry P/E: 20 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.07 <BR>Return on Equity: 3.44% <BR>Price to Book: 4.07 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Niva Bupa Health?

As of 10th June, Niva Bupa Health Insurance Company Ltd has a market capitalization of 15,497.00 Cr and reported net sales of 6067.57 Cr and a net profit of 130.78 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Niva Bupa Health Insurance Company Ltd has a market capitalization of 15,497.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 6067.57 Cr, while the sum of Net Profit for the same period is 130.78 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 3,776.22 Cr, and Total Assets amount to 9,760.16 Cr.

Who are the peers of the Niva Bupa Health?

Niva Bupa Health's peers include HDFC Life, ICICI Lombard, Max Financial, and Star Health, among others. It shows good growth and average management risk, with a 1-year return of 1.95%, lower than Star Health's 12.98% but higher than Medi Assist's -29.51%.

Peers: The peers of Niva Bupa Health are HDFC Life Insur., ICICI Lombard, ICICI Pru Life, General Insuranc, Max Financial, Star Health Insu, Go Digit General, New India Assura, and Medi Assist Ser.<BR><BR>Quality Snapshot: Excellent management risk is observed at ICICI Lombard and Go Digit General, while Average management risk is found at HDFC Life Insur., ICICI Pru Life, General Insuranc, Max Financial, Star Health Insu, and Niva Bupa Health, and the rest. Good management risk is noted at Medi Assist Ser. Below Average management risk is present at New India Assura. In terms of Growth, Good growth is seen at Niva Bupa Health and Go Digit General, while Average growth is found at HDFC Life Insur., ICICI Lombard, General Insuranc, and Medi Assist Ser., and the rest. Below Average growth is noted at ICICI Pru Life, Max Financial, and Star Health Insu, along with New India Assura. Excellent capital structure is observed across all peers.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Star Health Insu at 12.98%, while the peer with the lowest is Medi Assist Ser. at -29.51%. Niva Bupa Health's 1-year return is 1.95%, which is higher than Medi Assist Ser. but lower than Star Health Insu. Additionally, the peers with negative six-month returns include Medi Assist Ser., Max Financial, and New India Assura.

Is Niva Bupa Health technically bullish or bearish?

As of November 28, 2025, Niva Bupa Health's technical stance is bearish due to negative indicators like a bearish MACD and moving averages, despite a mildly bullish signal from Dow Theory.

As of 28 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Niva Bupa Health is bearish, with a moderate strength. Key indicators driving this stance include the bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands and moving averages on the daily timeframe, and a bearish KST on the weekly. Although the Dow Theory indicates a mildly bullish signal on the weekly, it is outweighed by the overall bearish indicators. The stock has underperformed against the Sensex year-to-date and over the past year, further supporting the bearish outlook.

How has been the historical performance of Niva Bupa Health?

Niva Bupa Health experienced significant growth from March 2024 to March 2025, with net sales rising to 4,894.46 Cr and profit after tax increasing to 213.52 Cr, while total assets grew to 9,760.16 Cr. The company improved its operating profit margin to 1.19% and enhanced cash flow from operating activities to 1,654.00 Cr.

Answer:<BR>The historical performance of Niva Bupa Health shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Niva Bupa Health's net sales increased from 3,811.25 Cr in March 2024 to 4,894.46 Cr in March 2025, while other operating income rose from 304.22 Cr to 479.82 Cr, leading to a total operating income of 5,374.28 Cr, up from 4,115.47 Cr. Total expenditure, excluding depreciation, also increased to 5,316.18 Cr from 4,254.40 Cr, with employee costs rising slightly and manufacturing expenses significantly increasing from 3,000.37 Cr to 4,061.10 Cr. The company turned around its operating profit, achieving 213.52 Cr in March 2025 compared to 81.85 Cr in March 2024, with a notable improvement in operating profit margin from -3.65% to 1.19%. Profit after tax also saw a substantial increase from 81.85 Cr to 213.52 Cr, resulting in a PAT margin growth from 2.15% to 4.36%. On the balance sheet, total assets grew from 6,191.86 Cr to 9,760.16 Cr, driven by an increase in non-current investments from 5,458.23 Cr to 8,175.08 Cr. Shareholder's funds rose significantly from 2,982.62 Cr to 3,776.22 Cr, while total liabilities increased to 9,760.16 Cr from 6,191.86 Cr. Cash flow from operating activities improved to 1,654.00 Cr from 812.00 Cr, although cash flow from investing activities worsened to -2,347.00 Cr from -1,881.00 Cr. The closing cash and cash equivalents increased to 220.00 Cr from 142.00 Cr, reflecting a positive cash flow trend.

Is Niva Bupa Health overvalued or undervalued?

As of November 27, 2024, Niva Bupa Health is considered very expensive and overvalued, with a PE ratio of 71.14 and significant underperformance at -0.62% year-to-date compared to the Sensex's 5.54%.

As of 27 November 2024, the valuation grade for Niva Bupa Health has moved from does not qualify to very expensive. The company is currently considered overvalued, with a PE ratio of 71.14, an EV to EBITDA ratio of 263.82, and a Price to Book Value of 7.37. These metrics significantly exceed those of its peers, such as Life Insurance with a PE ratio of 12.54 and Bajaj Finance Ltd. at 35.01, indicating a stark contrast in valuation.<BR><BR>In comparison to the broader market, Niva Bupa Health has underperformed, with a year-to-date return of -0.62% against the Sensex's 5.54%. This underperformance, coupled with its high valuation ratios, reinforces the conclusion that the company is overvalued in the current market environment.

Who are the top shareholders of the Niva Bupa Health?

The top shareholders of Niva Bupa Health are Bupa Singapore Holdings Pte Ltd with 55.98%, followed by foreign institutional investors at 8.9%, mutual funds at 2.68%, and individual investors at 4.23%. There are no pledged promoter holdings, reflecting strong promoter commitment.

The top shareholders of Niva Bupa Health include Bupa Singapore Holdings Pte Ltd, which holds a significant 55.98% of the company. The majority of the remaining shares are held by mutual funds, which account for 2.68% across 14 schemes, and foreign institutional investors (FIIs), who hold 8.9% through 42 different entities. Additionally, individual investors collectively own 4.23% of the shares. Notably, there are no pledged promoter holdings, indicating a strong commitment from the promoters.

Has Niva Bupa Health declared dividend?

No Dividend History Available